Product
Quadrivalent Recombinant Influenza Vaccine
Aliases
Flublok Quadrivalent®
5 clinical trials
2 indications
Indication
Influenza ImmunizationIndication
InfluenzaClinical trial
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2024-04-02
Clinical trial
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and AboveStatus: Recruiting, Estimated PCD: 2025-05-22
Clinical trial
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2024-01-19
Clinical trial
A Phase III Randomized, Modified Double-blind, Active-controlled, Multi-center Study to Describe the Immunogenicity and Safety of the Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South KoreaStatus: Completed, Estimated PCD: 2022-09-01
Clinical trial
A Phase I, Parallel, Randomized, Active-controlled, Multi-center, Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adults 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2023-02-17